Search
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis
Tanespimycin
go.drugbank.com/drugs/DB05134InvestigationalTanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous le...
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedIn the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.
Distigmine
go.drugbank.com/drugs/DB13694InvestigationalDistigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].
Human Embryonic Stem Cell-derived M Cell
go.drugbank.com/drugs/DB15734InvestigationalIMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Muromonab
go.drugbank.com/drugs/DB00075ApprovedInvestigationalWithdrawnMore specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.
beta-Alanine
go.drugbank.com/drugs/DB03107Investigationalbeta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].